Sign in
WithdrawnNo phase

Safety and Efficacy of IrisFIT™ Patent Foramen Ovale Occluders

Key facts

Who runs it
Lifetech Scientific (Shenzhen) Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
12 Apr 2022
Expected to end
31 Mar 2028
Type of study
Interventional
Treatments tested
  • Iris FIT™ PFO closure system
Record updated
14 March 2023
Why it stopped
Company policy

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (26)Hide the full registry criteria

Who can take part

  • Patients aged 18-60 years
  • Be able to understand the purpose of the experiment, voluntarily participate in the experiment and sign the informed consent
  • Patent foramen ovale was confirmed by chest ultrasound (TTE) or esophageal ultrasound (TEE)
  • The presence of a large right-to-left shunt was confirmed by right aspiration angiography (cTTE or cTCD)
  • It meets the clinical status of patent foramen ovale plugging indication, and at least one of the following conditions exists:; Cryptogenic stroke complicated with patent foramen ovale, combined with one or more clinical risk factors; Cryptogenic stroke complicated with patent foramen ovale, combined with one or more anatomical risk factors of patent foramen ovale; Cryptogenic stroke complicated with patent foramen ovale, with clear deep vein thrombosis or pulmonary embolism, and not suitable for anticoagulant therapy; Cryptogenic stroke complicated with patent foramen ovale, but still recurred with antiplatelet or anticoagulant therapy

Who cannot take part

  • Mitral/aortic disease: including mitral stenosis or severe mitral regurgitation of any cause, severe aortic stenosis or severe aortic regurgitation, mitral or aortic valve vegetations or prior valve replacement surgery
  • Participate in clinical trials of other drugs or medical devices within three months
  • intracardiac thrombosis or tumor, intracardiac neoplasm
  • acute myocardial infarction or unstable angina within 6 months
  • Left ventricular aneurysm formation or left ventricular wall movement disorder
  • Patients with active endocarditis or other untreated infections or other hemorrhagic diseases
  • Pulmonary hypertension or patent foramen ovale was a special channel
  • Uncontrolled hypertension (> 180/100 mmHg)
  • Contraindication of antiplatelet or anticoagulant therapy, such as severe bleeding within 3 months, obvious retinopathy, history of other intracranial bleeding, and obvious intracranial diseases
  • Coronary heart disease, hypertension, diabetes and other vascular diseases that are poorly controlled by drugs or other means
  • Thrombosis exists at the location or route of implantation
  • Malignant neoplasms or other diseases with a life expectancy of less than 2 years
  • Dilated cardiomyopathy, LVEF < 35%, or other severe heart failure
  • liver and kidney function impairment (ALT or AST > 3 times the upper limit of normal value, serum creatinine (Cr) > 2 times the upper limit of normal value)
  • Carotid atherosclerotic stenosis was determined by the investigator based on CT or vascular ultrasound (> 50%)
  • Large cerebral infarction occurred within 4 weeks (MR/CT or DWI image ASPECTS score <6 points or infarction volume ≥70 ml or infarction area > 1/3 middle cerebral artery blood supply area)
  • Patients with right-to-left shunt due to other causes, including atrial septal defect or perforated diaphragm
  • Atrial fibrillation/atrial flutter (chronic or intermittent)
  • pregnant or planning to become pregnant during the trial
  • The investigator determined that the patient was not suitable for implantation of PFO occluder (for example, the diameter of the base of the atrial septal tumor ≥25mm and the size of the foramen ovale ≥5mm) or the patient has contraindications for implantation of PFO occluder
  • Patients who could not be followed up during the trial

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the performance of patent foramen ovale (PFO) device developed by Lifetech Technology (Shenzhen) Co., LTD

The group in the trial

  • Intervention armTreatment being tested

    Patients with cryptogenic stroke complicated with patent foramen ovale,and passed the screening and signed the informed consent form

    Treatment: Iris FIT™ PFO closure system

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multi-Center, Single-Group Goal Value Clinical Trial to Revaluate the Safety and Efficacy of Patent Foramen Ovale Occluders
Record updated
14 March 2023